Download PDF
Klin Monbl Augenheilkd 2007; 224(7): 559-566
DOI: 10.1055/s-2007-963356
Statement

© Georg Thieme Verlag KG Stuttgart · New York

Stellungnahme der Retinologischen Gesellschaft, der Deutschen Ophthalmologischen Gesellschaft und des Berufsverbands der Augenärzte Deutschlands zu aktuellen therapeutischen Möglichkeiten bei der neovaskulären altersabhängigen Makuladegeneration

Stand Juni 2007Position of the Retinological Society, the German Ophthalmological Society and the Professional Association of Ophthalmologists in Germany on the Current Therapeutic Possibilities for Neovascular Age-related Macular DegenerationStatus as of June 2007Die redaktionellen Mitarbeiter sind am Ende des Beitrags gelistet.
Further Information

Publication History

Eingegangen: 21.6.2007

Angenommen: 25.6.2007

Publication Date:
26 July 2007 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die Rahmenbedingungen in der Behandlung der exsudativen AMD[1] haben sich seit der letzten Stellungnahme der Fachgesellschaften erheblich verändert. Nach der Zulassung von Pegaptanib zur intraokularen Therapie der AMD ist seit Februar 2007 auch Ranibizumab in Deutschland zugelassen. Zusätzlich ist die Qualitätssicherungsvereinbarung zur photodynamischen Therapie am Augenhintergrund novelliert worden, wobei neue Bestimmungen zur Behandlung der okkulten CNV aufgenommen wurden und dem Vorschlag der Fachgesellschaften zur Präzisierung der Nomenklatur sub- bzw. extrafovealer CNVs gefolgt wurde. Es war deshalb notwendig, die Empfehlungen der Fachgesellschaften zur Therapie der AMD den geänderten Rahmenbedingungen anzupassen.

Abstract

The basic conditions in the management of exudative age-related macular degeneration have changed considerably since the last statement of the German professional associations in 2006. While Pegaptanib was approved in Germany already in 2006 Ranibizumab was approved for the treatment of exudative macular degeneration in Germany in February 2007. More over the quality assurance regulations for the photodynamic treatment of choroidal neovascularizations with Verteporfin were modified including the treatment of occult lesions and implementing a simplified classification of extra- and subfoveal lesions. Consequently modification of the recommendations for the non-surgical treatment of exudative age-related macular degeneration appeared inevitable.

Schlüsselwörter

altersabhängige Makuladegeneration - Behandlungsrichtlinien

Key words

age related macular degeneration - preferred practice pattern

1 Ein Glossar mit den verwendeten Abkürzungen findet sich am Ende des Textes.

Literatur

  • 1 Stellungnahme zu aktuellen therapeutischen Möglichkeiten bei der neovaskularen altersabhängigen Makuladegeneration.  Klin Monatsbl Augenheilkd. 2006;  223 271-278
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Bekanntmachungen: Vereinbarung von Qualitätssicherungsmaßnahmen nach § 135 Abs. 2 SGB V zur photodynamischen Therapie am Augenhintergrund (Qualitätssicherungsvereinbarung PDT).  Dtsch Ärztebl. 2006;  103 A 2575-2577
    PubMedGoogle Scholar
  • 3 Bekanntmachungen: Beschluss des Gemeinsamen Bundesausschusses über eine Änderung der Richtlinie Methoden vertragsärztliche Versorgung in Anlage I „Anerkannte Untersuchungs- oder Behandlungsmethoden” vom 19. September 2006.  Dtsch Ärztebl. 2006;  104 A-74
    PubMedGoogle Scholar
  • 4 Pauleikhoff D, Bornfeld N, Gabel V P. et al . Konsenspapier der Retinologischen Gesellschaft, der Deutschen Ophthalmologischen Gesellschaft und des Berufsverbandes der Augenärzte - Stellungnahme zur aktuellen Therapie der neovaskulären AMD.  Klin Monatsbl Augenheilkd. 2005;  222 381-388
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 http://www.novartisophthalmics.visudyne.de/Visudyne/index_pro.xml?view = db&menuid = 1663&linkid = 3859
  • 6 Gillies M C, Simpson J M, Luo W. et al . A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: one-year results.  Arch Ophthalmol. 2003;  121 667-673
    CrossrefPubMedGoogle Scholar
  • 7 Jonas J B, Spandau U H, Kamppeter B A. et al . Duration of the effect of intravitreal triamcinolone acetonide in eyes with exudative age-related macular degeneration.  J Ocul Pharmacol Ther. 2006;  22 194-199
    PubMedGoogle Scholar
  • 8 Jonas J B, Spandau U H, Kamppeter B A. et al . Repeated intravitreal injection of triamcinolone for exudative age-related macular degeneration.  Ophthalmic Res. 2006;  38 324-328
    CrossrefPubMedGoogle Scholar
  • 9 Jonas J B, Spandau U H, Kamppeter B A. et al . Follow-up after intravitreal triamcinolone acetonide for exudative age-related macular degeneration.  Eye. 2007;  21 387-394
    CrossrefPubMedGoogle Scholar
  • 10 Russell S R, Hudson H L, Jerdan J A. Anecortave acetate for the treatment of exudative age-related macular degeneration - a review of clinical outcomes.  Surv Ophthalmol. 2007;  52 (Suppl 1) S79-90
    CrossrefPubMedGoogle Scholar
  • 11 Slakter J S, Bochow T W, D’Amico D J. et al . Anecortave acetate (15 milligrams) versus photodynamic therapy for treatment of subfoveal neovascularization in age-related macular degeneration.  Ophthalmology. 2006;  113 3-13
    CrossrefPubMedGoogle Scholar
  • 12 Gonzales C R. Enhanced efficacy associated with early treatment of neovascular age-related macular degeneration with pegaptanib sodium: an exploratory analysis.  Retina. 2005;  25 815-827
    CrossrefPubMedGoogle Scholar
  • 13 Gragoudas E S, Adamis A P, Cunningham E T Jr. et al . Pegaptanib for neovascular age-related macular degeneration.  N Engl J Med. 2004;  351 2805-2816
    CrossrefPubMedGoogle Scholar
  • 14 Chakravarthy U, Adamis A P, Cunningham E T Jr. et al . Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration.  Ophthalmology. 2006;  113 1508-1521
    PubMedGoogle Scholar
  • 15 Hughes M S, Sang D N. Safety and efficacy of intravitreal bevacizumab followed by pegaptanib maintenance as a treatment regimen for age-related macular degeneration.  Ophthalmic Surg Lasers Imaging. 2006;  37 446-454
    PubMedGoogle Scholar
  • 16 Brown D M, Kaiser P K, Michels M. et al . Ranibizumab versus verteporfin for neovascular age-related macular degeneration.  N Engl J Med. 2006;  355 1432-1444
    CrossrefPubMedGoogle Scholar
  • 17 Rosenfeld P J, Brown D M, Heier J S. et al . Ranibizumab for neovascular age-related macular degeneration.  N Engl J Med. 2006;  355 1419-1431
    CrossrefPubMedGoogle Scholar
  • 18 Novartis Pharma GmbH .Fachinformation Lucentis®. Rote Liste GmbH 2007
    Google Scholar
  • 19 http://www.novartis.de/Lucentis
  • 20 Liew G, Mitchell P. Ranibizumab for neovascular age-related macular degeneration.  N Engl J Med. 2007;  356 747-748
    CrossrefPubMedGoogle Scholar
  • 21 Heiduschka P, Fietz H, Hofmeister S. et al . Penetration of bevacizumab through the retina after intravitreal injection in the monkey.  Invest Ophthalmol Vis Sci. 2007;  48 2814-2823
    CrossrefPubMedGoogle Scholar
  • 22 Spitzer M S, Yoeruek E, Sierra A. et al . Comparative antiproliferative and cytotoxic profile of bevacizumab (Avastin), pegaptanib (Macugen) and ranibizumab (Lucentis) on different ocular cells.  Graefes Arch Clin Exp Ophthalmol. 2007;  im Druck
    PubMedGoogle Scholar
  • 23 Moschos M M, Brouzas D, Apostolopoulos M. et al . Intravitreal use of bevacizumab (Avastin) for choroidal neovascularization due to ARMD: a preliminary multifocal-ERG and OCT study: Multifocal-ERG after use of bevacizumab in ARMD.  Doc Ophthalmol. 2007;  114 37-44
    CrossrefPubMedGoogle Scholar
  • 24 Bakri S J, Snyder M R, Pulido J S. et al . Six-month stability of bevacizumab (Avastin) binding to vascular endothelial growth factor after withdrawal into a syringe and refrigeration or freezing.  Retina. 2006;  26 519-522
    CrossrefPubMedGoogle Scholar
  • 25 Peters S, Julien S, Heiduschka P. et al . Anti-permeability and anti-proliferative effects of standard and frozen bevacizumab on choroidal endothelial cells.  Br J Ophthalmol. 2007;  91 827-831
    CrossrefPubMedGoogle Scholar
  • 26 Chen C Y, Wong T Y, Heriot W J. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration: a short-term study.  Am J Ophthalmol. 2007;  143 510-512
    CrossrefPubMedGoogle Scholar
  • 27 Aisenbrey S, Ziemssen F, Volker M. et al . Intravitreal bevacizumab (Avastin) for occult choroidal neovascularization in age-related macular degeneration.  Graefes Arch Clin Exp Ophthalmol. 2007;  245 941-948
    CrossrefPubMedGoogle Scholar
  • 28 Yoganathan P, Deramo V A, Lai J C. et al . Visual improvement following intravitreal bevacizumab (Avastin) in exudative age-related macular degeneration.  Retina. 2006;  26 994-998
    CrossrefPubMedGoogle Scholar
  • 29 Jonas J B, Libondi T, Ihloff A K. et al . Visual acuity change after intravitreal bevacizumab for exudative age-related macular degeneration in relation to subfoveal membrane type.  Acta Ophthalmol Scand. 2007; im Druck; 
    PubMedGoogle Scholar
  • 30 Mennel S, Callizo J, Schmidt J C. et al . Acute retinal pigment epithelial tear in the untreated fellow eye following repeated bevacizumab (Avastin®) injections.  Acta Ophthalmol Scand. 2007; im Druck; 
    PubMedGoogle Scholar
  • 31 Avery R L, Pearlman J, Pieramici D J. et al . Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy.  Ophthalmology. 2006;  113 1695-1705
    CrossrefPubMedGoogle Scholar
  • 32 Fung A E, Rosenfeld P J, Reichel E. The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide.  Br J Ophthalmol. 2006;  90 1344-1349
    CrossrefPubMedGoogle Scholar
  • 33 Kernt M, Neubauer A S, Kampik A. Intravitreal bevacizumab (Avastin) treatment is safe in terms of intraocular and blood pressure.  Acta Ophthalmol Scand. 2007;  85 119-120
    CrossrefPubMedGoogle Scholar
  • 34 Aggio F B, Farah M E, Melo G B. et al . Acute endophthalmitis following intravitreal bevacizumab (Avastin) injection.  Eye. 2007;  21 408-409
    CrossrefPubMedGoogle Scholar
  • 35 Gelisken de F, Ziemssen F, Voelker M. et al . Retinal pigment epithelial tear following intravitreal bevacizumab injection for neovascular age-related macular degeneration.  Acta Ophthalmol Scand. 2006;  84 833-834
    CrossrefPubMedGoogle Scholar
  • 36 Meyer C H, Mennel S, Schmidt J C. et al . Acute retinal pigment epithelial tear following intravitreal bevacizumab (Avastin) injection for occult choroidal neovascularisation secondary to age related macular degeneration.  Br J Ophthalmol. 2006;  90 1207-1208
    CrossrefPubMedGoogle Scholar
  • 37 Spaide R F, Sorenson J, Maranan L. Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization.  Ophthalmology. 2003;  110 1517-1525
    CrossrefPubMedGoogle Scholar
  • 38 Spaide R F, Sorenson J, Maranan L. Combined photodynamic therapy and intravitreal triamcinolone for nonsubfoveal choroidal neovascularization.  Retina. 2005;  25 685-690
    CrossrefPubMedGoogle Scholar
  • 39 Augustin A J, Schmidt-Erfurth U. Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration.  Ophthalmology. 2006;  113 14-22
    CrossrefPubMedGoogle Scholar
  • 40 Spaide R F. Rationale for combination therapies for choroidal neovascularization.  Am J Ophthalmol. 2006;  141 149-156
    CrossrefPubMedGoogle Scholar
  • 41 Jonas J B, Kreissig I, Spandau U H. et al . Infectious and noninfectious endophthalmitis after intravitreal high-dosage triamcinolone acetonide.  Am J Ophthalmol. 2006;  141 579-580
    CrossrefPubMedGoogle Scholar
  • 42 Augustin A J, Schmidt-Erfurth U. Verteporfin and intravitreal triamcinolone acetonide combination therapy for occult choroidal neovascularization in age-related macular degeneration.  Am J Ophthalmol. 2006;  141 638-645
    CrossrefPubMedGoogle Scholar
  • 43 Chan W M, Lai T Y, Wong A L. et al . Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of subfoveal choroidal neovascularisation in age related macular degeneration: a comparative study.  Br J Ophthalmol. 2006;  90 337-341
    CrossrefPubMedGoogle Scholar
  • 44 Liggett P E, Colina J, Chaudhry N A. et al . Triple therapy of intravitreal triamcinolone, photodynamic therapy, and pegaptanib sodium for choroidal neovascularization.  Am J Ophthalmol. 2006;  142 1072-1074
    CrossrefPubMedGoogle Scholar
  • 45 Augustin A J, Puls S, Offermann I. Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone.  Retina. 2007;  27 133-140
    CrossrefPubMedGoogle Scholar
  • 46 Shen J, Samul R, Silva R L. et al . Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1.  Gene Ther. 2006;  13 225-234
    CrossrefPubMedGoogle Scholar
  • 47 Wijngaarden van P, Coster D J, Williams K A. Inhibitors of ocular neovascularization: promises and potential problems.  JAMA. 2005;  293 1509-1513
    CrossrefPubMedGoogle Scholar
  • 48 http://www.cebm.net/downloads/Oxford_CEBM_Levels_5.rtf
  • 49 Francke R, Hart D. Off label use - Arzneimittelrechtliche, haftungsrechtliche, berufsrechtliche und sozialrechtliche Fragen.  Die Sozialgerichtsbarkeit. 2003;  50 653-664
    PubMedGoogle Scholar
  • 50 Parrish R 2nd , Sternberg P Jr. Does „off-label” mean off limits for patient care?.  Am J Ophthalmol. 2007;  143 853-855
    CrossrefPubMedGoogle Scholar
  • 51 Macular Photocoagulation Study Group . Argon laser photocoagulation for neovascular maculopathy. Five-year results from randomized clinical trials.  Arch Ophthalmol. 1991;  109 1109-1114
    PubMedGoogle Scholar
  • 52 Voelker M, Gelisken F, Ziemssen F. et al . Verteporfin photodynamic therapy for extrafoveal choroidal neovascularisation secondary to age-related macular degeneration.  Graefes Arch Clin Exp Ophthalmol. 2005;  243 1241-1246
    CrossrefPubMedGoogle Scholar
  • 53 Dhalla M S, Shah G K, Blinder K J. et al . Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration.  Retina. 2006;  26 988-993
    CrossrefPubMedGoogle Scholar
  • 54 Axer-Siegel R, Ehrlich R, Rosenblatt I. et al . Photodynamic therapy for occult choroidal neovascularization with pigment epithelium detachment in age-related macular degeneration.  Arch Ophthalmol. 2004;  122 453-459
    CrossrefPubMedGoogle Scholar
  • 55 Axer-Siegel R, Ehrlich R, Avisar I. et al . Combined photodynamic therapy and intravitreal triamcinolone acetonide injection for neovascular age-related macular degeneration with pigment epithelium detachment.  Ophthalmic Surg Lasers Imaging. 2006;  37 455-461
    PubMedGoogle Scholar
  • 56 Sutter F K, Kurz-Levin M M, Fleischhauer J. et al . Macular atrophy after combined intravitreal triamcinolone acetonide (IVTA) and photodynamic therapy (PDT) for retinal angiomatous proliferation (RAP).  Klin Monatsbl Augenheilkd. 2006;  223 376-378
    Article in Thieme ConnectPubMedGoogle Scholar
  • 57 Nicolo M, Ghiglione D, Lai S. et al . Retinal angiomatous proliferation treated by intravitreal triamcinolone and photodynamic therapy with verteporfin.  Graefes Arch Clin Exp Ophthalmol. 2006;  244 1336-1338
    CrossrefPubMedGoogle Scholar
  • 58 Bolz M, Michels S, Geitzenauer W. et al . Effect of systemic bevacizumab therapy on retinal pigment epithelial detachment.  Br J Ophthalmol. 2006;  91 785-789
    PubMedGoogle Scholar
  • 59 Gamulescu M A, Framme C, Sachs H. RPE-rip after intravitreal bevacizumab (Avastin) treatment for vascularised PED secondary to AMD.  Graefes Arch Clin Exp Ophthalmol. 2007;  245 1037-1040
    CrossrefPubMedGoogle Scholar
  • 60 Aiello L P, Brucker A J, Chang S. et al . Evolving guidelines for intravitreous injections.  Retina. 2004;  24 S3-S19
    CrossrefPubMedGoogle Scholar
  • 61 Scott I U, Flynn H W Jr. Reducing the risk of endophthalmitis following intravitreal injections.  Retina. 2007;  27 10-12
    CrossrefPubMedGoogle Scholar

1 Ein Glossar mit den verwendeten Abkürzungen findet sich am Ende des Textes.

2 Die Mitglieder der Makulakommission finden sich unter http://www.dog.org/dog/kommissionen.html#Makula.